Phase 1/2 Study of TROP2 CAR NK Cells with Belzutifan in Pancreatic Cancer
A Phase I/II study is underway to evaluate TROP2 CAR/IL-15 engineered NK cells combined with belzutifan in pancreatic cancer.
Therapeutic Area
Therapeutic area intelligence for CAR-NK Cells with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.